Walter P. Hölzle, president of vips, discusses the current priorities of the association, the importance of innovation, and the challenges of the current pricing system.
While growth is close to zero for many pharmaceutical markets in Europe, Swiss pharma spending increased 4.5 percent in 2015. What would you identify as the main drivers of this growth?
"There is an increased cost to treating these ever growing numbers of patients living with chronic illnesses, but one that Swiss society is happy to pay to ensure a happy, healthy, and productive workforce."
